{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Hematologic Cancers

Purpose of Activity

To present the latest information about advances in treatments for hematologic cancers.

Learning Objectives/Outcomes

After completing this continuing education activity you will be able to:

  1. Identify recent advances in the use of monoclonal antibodies to treat multiple myeloma.
  2. Recognize the role of hematopoietic stem cell transplantation (HSCT) in treating patients with Cutaneous T-Cell Lymphoma (CTCL) and chronic myelogenous leukemia (CML).
  3. Discern appropriate monitoring guidelines to assess the response of patients to tyrosine kinase inhibitors (TKIs)
Price: $21.95

Credits:

  • ANCC 2.0 CH
  • DC - BON 2.0 CH
  • FL - BON 2.0 CH
  • GA - BON 2.0 CH

Lippincott Williams & Wilkins is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Williams & Wilkins is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, #50-1223, Florida Board of Nursing, #50-1223, and Georgia Board of Nursing, #50-1223. Your certificate is valid in all states.







Test Code: OT1215
Published: Dec 2015
Expires: 12/3/2021
Sources: Oncology Times
Passing Score: 10/13 (76%)
Authors: Mark L. Fuerst; Sarah DiGiulio; Heather Lindsey
Specialties: Oncology